RRx-001

Phase 2Small molecule

EEpicentRx, Inc.

RRx-001 is one of 25 small molecule programs targeting Oral Mucositis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oral MucositisCompleted

Oral MucositisPhase 2

Completed

Competition

Competitive Landscape

26 competitors in Oral Mucositis

#DrugCompanyPhaseTrials

Thalomid

Bristol-Myers Squibb

Approved

—2

MS Contin

HHikma Pharmaceuticals LLC

Approved

2 3

Levaquin

WWim Janssens

Approved

1 4

Alka-Seltzer

AAbbott

Approved

1 5

Acetadote

AArbor Pharmaceuticals, Inc.

Mycostatin

Betadine

BBecton, Dickinson and Company

Approved

—8

Peridex

DDexcel Pharma Technologies Ltd.

Approved

—9

Heparin Sodium

BBaxter Healthcare Corporation

Catapres

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

Oral Mucositis

NCT05966194

Clinical

Trials by Indication[1]

Oral Mucositis2 trials

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

Completed·EEpicentRx, Inc.·Phase 2·NCT03515538·53 enrolled

A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Active, not recruiting·EEpicentRx, Inc.·Phase 2·NCT05966194·216 enrolled

Cancer1 trial

Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects

Completed·EEpicentRx, Inc.·Phase 1·NCT01359982·26 enrolled

Metastatic Colorectal Cancer1 trial

A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Completed·EEpicentRx, Inc.·Phase 2·NCT02096354·62 enrolled

Central Nervous System Tumor1 trial

RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

Terminated·EEpicentRx, Inc.·Phase 1·NCT04525014·2 enrolled

Ovarian Cancer1 trial

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Completed·EEpicentRx, Inc.·Phase 2·NCT02489903·139 enrolled

7 more indications

Pilot Study1 trial

A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

Terminated·EEpicentRx, Inc.·Phase 1·NCT02096341·2 enrolled

Advanced Cancer1 trial

RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)

Terminated·EEpicentRx, Inc.·Phase 1·NCT02801097·28 enrolled

Small Cell Lung Cancer1 trial

A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer

Active, not recruiting·EEpicentRx, Inc.·Phase 3·NCT05566041·292 enrolled

Whole Brain Radiation1 trial

Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases

Completed·EEpicentRx, Inc.·Phase 1·NCT02215512·29 enrolled

Glioblastoma1 trial

RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas

Completed·EEpicentRx, Inc.·Phase 1·NCT02871843·19 enrolled

Nivolumab1 trial

A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab

Completed·EEpicentRx, Inc.·Phase 1·NCT02518958·12 enrolled

Cholangiocarcinoma1 trial

RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

Terminated·EEpicentRx, Inc.·Phase 2·NCT02452970·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for RRx-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RRx-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RRx-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EpicentRx, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEpicentRx, Inc.

RRx-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Oral Mucositis2 trials

Cancer1 trial

Metastatic Colorectal Cancer1 trial

Central Nervous System Tumor1 trial

Ovarian Cancer1 trial

Pilot Study1 trial

Advanced Cancer1 trial

Small Cell Lung Cancer1 trial

Whole Brain Radiation1 trial

Glioblastoma1 trial

Nivolumab1 trial

Cholangiocarcinoma1 trial

References

Drug Info

Quick Facts

Related News